# Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase

> **NCT07091747** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Federal University of Latin American Integration** · enrollment: 61 (actual)

## Conditions studied

- Alzheimer Disease (AD)

## Interventions

- **OTHER:** Cannabis 50 mg of CBD and 5 mg of THC

## Key facts

- **NCT ID:** NCT07091747
- **Lead sponsor:** Federal University of Latin American Integration
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2025-12-12
- **Final completion:** 2025-12-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091747, "Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07091747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*